Three years watching the wrong thing.

Somewhere inside Novo Nordisk, most likely in an inbox nobody was watching, sat a renewal notice for a few hundred dollars. Nobody paid it. And so, quietly, in 2026, the company behind the most valuable drug franchise on the planet let one of its patents lapse over an unpaid fee that would not have covered dinner for four.

The franchise that patent helped guard is worth tens of billions.

The drug is semaglutide, sold as Ozempic and Wegovy, and in a single year it earned Novo more than twenty-six billion dollars. In Canada the core patent covering it fell, reportedly over that missed maintenance fee, and the door swung open for generic manufacturers as early as the start of the year. Sandoz and Apotex were already standing at it, waiting.

Told as a story about carelessness, this is a good anecdote and nothing more. A giant tripping over a clerical oversight. Told properly, it is the most instructive thing to happen in this market in three years, and not for the reason you would expect. The striking part is not that Novo lost the patent. The striking part is how little it mattered.

The thicket, not the molecule

Even with the compound patent gone in Canada, and with the same expiry landing across India, China, Brazil and a handful of other markets that between them carry close to half the world's obesity burden, cheap generic semaglutide is not about to flood the countries where most of you actually sell. In the United States, layered protections push a generic to roughly 2031. In the UK it is much the same. And tirzepatide, the bigger seller of the two under the names Mounjaro and Zepbound, is locked up well into the mid-2030s. The cliff everyone keeps pointing at is a long way off, and smaller than the headlines make it look.

The reason is the whole point of this piece, so it is worth sitting with.

Novo never protected this franchise with one patent on the molecule. It built a thicket of more than two hundred of them, and the majority cover not the chemistry but the formulation and, above all, the delivery device. The pen.

That single fact turns the last three years of medtech anxiety completely on its head.

The threat that was pointing the wrong way

Cast your mind back to the story medtech has been telling itself since 2023. It was a story of siege. GLP-1 drugs would empty the bariatric theatres, and they duly did, with metabolic surgery among eligible patients falling by close to half in three years. They would make the sleep apnoea machine obsolete, and ResMed's share price flinched every time a trial readout suggested as much. The molecule was cast as the thing that would bury the device industry.

And yet the molecule cannot reach a single patient without a device.

The peer-reviewed costing work is blunt about it. Strip away the brand and the true manufacturing cost of generic injectable semaglutide could fall to somewhere between roughly twenty-eight and one hundred and forty dollars per patient per year. The part that stubbornly refuses to get cheaper, the part that contributes most of whatever cost remains, is the injection device. The molecule is nearly free. The pen is where the money and the legal protection actually live.

So the drug that was supposed to kill medtech turns out to be a hostage of medtech. The one defensible position in the entire GLP-1 gold rush was never the chemistry. It was the plastic around it.

Three companies who read the room

This is the pattern worth carrying out of the story, because it refuses to stay in one lane. The value in a market almost never sits where the crowd is looking, and the operators who came through this cycle intact were the ones who understood that early.

Take Fractyl Health, a device company whose entire commercial thesis rests on the drug's greatest weakness rather than its strength. Its Revita procedure targets the weight patients regain once they stop injecting, and most of them do stop, whether over cost, side effects, or simple fatigue with a lifelong needle. The drug's success manufactured the exact problem the device exists to solve. Fractyl is not competing with the molecule. It is building a market out of the moment the molecule fails.

ResMed did something quieter and just as shrewd. Rather than fight the drug, it reframed it, running physician education so that patients starting a GLP-1 get screened for sleep apnoea. It now points to nearly two million people using its devices who also hold a GLP-1 prescription. The trial data helped, showing the drug and the machine together outperforming the drug alone. A threat became a funnel.

And Novo itself, whether by design or by accident of history, proved the deepest version of the lesson: that when everyone is staring at the compound, the real estate worth owning is the thing you inject it with.

Three companies, one lesson. None of them won by owning the object everyone else was staring at. They won by reading where the value would settle once the noise died down, and getting there first.

The colder question

The commercial leaders who navigated this cycle were not the ones tracking the molecule. They were the ones who asked a colder question, and asked it early: when the obvious thing arrives to destroy your market, where does the defensible value actually migrate to?

The answer is hardly ever the thing in the headline. This time it was a device the size of a pen, and an entire industry spent three years watching the drug.

So it is worth turning the question on your own market before someone turns it on you. What is everyone in your sector staring at right now? And where has the value quietly moved while they stare?